𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neuroprotective Therapy for Parkinson's disease

✍ Scribed by I.Shoulson and the Parkinson Study Group

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
103 KB
Volume
7
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

In the context of degenerative disorders of the basal ganglia, neuroprotective therapy refers to interventions that preserve the integrity and function of vulnerable neurons and thereby slow or halt clinical decline. Decoppering therapy for Wilson's disease is the only established neuroprotective therapy, which not only forestalls decline but may reverse deficits and prevent the onset of illness in presymptomatic homozygotes. Based on our expanding knowledge of the pathogenesis of nigral degeneration, neuroprotective therapy may also be an achievable goal for Parkinson's disease.

πŸ“œ SIMILAR VOLUMES

Neuroprotective therapy in Parkinson's d
Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy
✍ C. Warren Olanow; Joseph Jankovic πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 78 KB πŸ‘ 1 views

The introduction of levodopa in the late 1960s represented a landmark in the therapy of Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have emerged as a major limitation of this otherwise effective therapy. Advancing medical and surgical treatment of these complic

Milacemide therapy for Parkinson's disea
Milacemide therapy for Parkinson's disease
✍ M. E. Giuffra; V. H. Sethy; T. L. Davis; M. M. Mouradian; Dr. T. N. Chase πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 303 KB

## Abstract The clinical effects of central glutamatergic stimulation by the glycine prodrug milacemide were studied in six patients with Parkinson's disease under double‐blind, placebo‐controlled conditions. When administered as monotherapy at a single oral dose of 1,200 mg, the drug increased ove

Gene therapy for Parkinson's disease
Gene therapy for Parkinson's disease
✍ Tomas Bjorklund; Jeffrey H. Kordower πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 133 KB

## Abstract The once fantastic theoretical concept that patients with Parkinson's disease (PD) would receive gene therapy in an attempt to alleviate their symptoms and potentially modify the course of their disease has become a reality. On the basis of positive preclinical data, four different gene